b. Current Recommendations. Current ACIP, or Control of Communicable
Disease Manual, recommendations and consultation with the relevant preventive
medicine authority are followed for the use of chemoprophylactic agents for the
following diseases, which have historically been shown to be of military significance:
Influenza
Meningococcal disease
Leptospirosis
Plague
Scrub typhus
Traveler's diarrhea
c. Malaria.
(1) Counseling. Comprehensive counseling on malaria prevention includes
mosquito avoidance, personal protective measures (clothing, repellents, bed netting,
etc.), and chemoprophylaxis is provided to military and civilian personnel considered at
risk of contracting malaria. Specific chemoprophylactic regimens are determined by
each of the Services based on degree and length of exposure and the prevalence of
drug resistant strains of Plasmodia in the area(s) of travel.
(2) Testing. Glucose-6-phosphate dehydrogenase (G6PD) testing should be
considered for individuals or units requiring primaquine chemoprophylaxis, especially
those of Mediterranean or North African descent. If a G6PD test is obtained, the test
result is recorded in the PHS Form 731 and the health record according to Service-
specific guidelines.
d. Group A Streptococcal Disease. Each military Service develops policies for
surveillance and prophylaxis of streptococcal disease at recruit centers.
7-21. BIOLOGICAL WARFARE DEFENSE
a. Purpose. DOD Directive 6205.3, DOD Immunization Program for Biological
Warfare Defense, establishes policy, assigns responsibilities, and prescribes
procedures for members of the DOD against validated biological warfare threats, and
prioritization of research, development, testing, acquisition, and stockpiling of biological
defense vaccines under Title 10, USC.
b. Responsibilities.
The Commanders of the Unified Commands, annually and as required,
provide the Chairman of the Joint Chiefs of Staff with their assessment of the biological
warfare threats to their theaters.
The Chair of the Armed Forces Epidemiological Board, in consultation
with the DOD Executive Agent and the Secretaries of the Military Departments, annually
MD0152
7-19